<DOC>
	<DOCNO>NCT01951885</DOCNO>
	<brief_summary>This randomize clinical trial study standard GVHD prophylaxis tacrolimus methotrexate compare tacrolimus , mycophenolate mofetil reduced-dose methotrexate patient hematologic malignancy undergo allogeneic hematopoietic cell transplant . Both mycophenolate mofetil reduced-dose methotrexate , combination calcineurin inhibitor , show safe effective GVHD prevention less toxicity standard dose methotrexate . It yet know , however , whether combination mycophenolate mofetil reduced-dose methotrexate tacrolimus effective tacrolimus standard dose methotrexate prevent GVHD .</brief_summary>
	<brief_title>Tac , Mini-MTX , MMF Versus Tac , MTX GVHD Prevention</brief_title>
	<detailed_description>Study Design This prospective randomize trial determine effectiveness different dos GVHD prophylaxis mucositis , engraftment aGVHD . Study consist two study group 50 subject . Group A receive Tac MTX ( 15 mg/m2 day +1 , 10 mg/m2 day +3 , +6 , +11 ) . Group B receive Tac , Mini-dose MTX ( 5 mg/m2 day +1 , +3 , +6 ) MMF .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients must one follow document disease : Chronic myelogenous leukemia Chronic lymphocytic leukemia Multiple myeloma Myelodysplasia Myeloproliferative disorder NonHodgkin 's lymphoma Hodgkin 's disease Acute myelogenous leukemia Acute lymphoblastic leukemia Acute biphenotypic leukemia Patients must undergo myeloablative allogeneic hematopoietic cell transplant one follow conditioning regimen : Busulfan ( ≥ 12.8 mg/kg IV PO ) cyclophosphamide ( ≥ 120 mg/kg ) Total body irradiation ( TBI ) ( ≥ 1200 cGy ) etoposide ( 60 mg/kg ) TBI ( ≥ 1200 cGy ) cyclophosphamide ( 120 mg/kg ) Patient must achieve complete morphologic remission prior start condition regimen Patient 's donor must relate unrelated human leukocyte antigen ( HLA ) 8/8 allelelevel match ( HLAA , B , C DRB1 ) Adult patient must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; pediatric patient must Lansky score ≥ 60 % Patients must life expectancy 100 day Patients must sign write informed consent Patients undergone prior transplant Patients seropositive human immunodeficiency virus ( HIV ) Patients medical illness concurrent psychiatric illness , investigator ' opinion , adequately controlled appropriate therapy Patients pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>